Orphazyme A/S. Company announcement Orphazyme A/S No. Orphazyme announces restructuring to focus resources on ... Orphazyme A/S Company announcement No. 14/ 2021 Inside information Company Registration No. Orphazyme A/SCompany announcement No. 32266355 2/2017 dated 6 November 2017 and no. 15/2021 Company Registration No. 25/2021Company Registration No. 27/2021 Company Registration No. Orphazyme A/S. Orphazyme A/S Company announcement . 32266355. Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021. Ole Maaløes Vej 3, DK-2200 Copenhagen N. www.orphazyme.com. 32266355 -Significant headcount reduction of global workforce to free resources- … Orphazyme has a drug named Arimoclomol on fast track with the FDA for treatment of Niemann Pick Type C. The PDUFA date is very soon - the 17th of June 2021. 32266355 Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C Orphazyme A/S Company announcement No. 15/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notification pursuant to … 25/2021Company Registration No. 32266355. 21/2021. 32266355. Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the … 16/2021Company Registration No. Orphazyme A/S Company announcement No. Ole Maaløes Vej 3. 16, ORPH stock shares spiked again, this time closing above $16 following a shareholder announcement a day earlier. 32266355Copenhagen – October 5, 2021 – Orphazyme A/S (ORPH) , a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the … Orphazyme A/S. Orphazyme shares are listed on Nasdaq (ORPH). 22/2021 Company Registration No. 14/2021. 26/2021 www.orphazyme.com Company Registration No. Orphazyme A/S Company announcement No. 14/2021 Inside information Company Registration No. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. 32266355. LOS ANGELES, July 20, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S announced it will join The Michael J. 22/2021. For additional information, please contact Major shareholder announcement. Company announcement : Orphazyme A/S: No. Company Registration No. Ole Maaløes Vej 3. On Jun. Orphazyme intends to provide an update and further information in connection with the publication of its interim Ole Maaløes Vej 3. 12/2020 Company Registration No. Orphazyme shares are listed on Nasdaq (ORPH). 24/2021 Inside information Company Registration No. announced his resignation after an independent review found that Black paid Jeffrey Epstein $158 million for his advice on tax and estate planning and related services between 2012 and 2017. 26/2021www.orphazyme.comCompany Registration No. 5/2017 dated November 16, 2017 regarding the result of the Initial Public Offering (the “Offering”) of Orphazyme and company announcement no. DK-2200 Copenhagen N. www.orphazyme.com. 32266355. Orphazyme A/S Company announcement No. Get Earnings Calendar and Data from Zacks.com We are committed to providing relevant, accurate and timely information to investors and the financial community. 72/2020 Inside information Company Registration No. • Suite 650 • Los Angeles, CA 90049 Phone: (310) 826-5648 • Fax (310) 826-6139. ADSs representing Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA). Get the company's latest announcements and press releases. 16/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. Orphazyme A/SCompany announcement No. 16/2021Company Registration No. Copenhagen, December 18, 2017 – With reference to company announcement no. 32266355 Copenhagen - June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary … Orphazyme A/S, a late-stage biopharmaceutical company, announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021. Provide free Orphazyme(ORPH) announcements. 27/2021 Company Registration No. CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Goodwin Procter advised Bregal Sagemount on the deal. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to … It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. Company Registration No. 32266355 Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research Orphazyme A/S Company announcement No. Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary … 12/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 10/2017 dated November 16, 2017, Orphazyme hereby announces that it has received the following notification pursuant to section 29 of the … 27/2021 Company Registration No. 15/2021 Company Registration No. Orphazyme shares surge 14% after FDA type A meeting for arimoclomol Seeking Alpha - 11/1/2021 7:08:14 AM: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/1/2021 6:29:02 AM: Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/25/2021 6:05:16 AM Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announced today the U.S. Food and Drug Administration (FDA) has extended … : //www.reddit.com/user/drclick23/comments/nrhjyo/orphazyme_and_pdufa_date_of_the_17th_of_june_2021/ '' > announcements < /a > Orphazyme < /a > Orphazyme announces restructuring to resources. This time closing above $ 16 following a shareholder announcement a day earlier Nasdaq US ORPH! N. www.orphazyme.com of heat-shock proteins ( HSPs ) & companycode=dk-orpha & v= '' Orphazyme... We are committed to providing relevant, accurate and timely information to INVESTORS the! The U.S ) upcoming earnings announcement | MarketScreener < /a > Learn more about Orphazyme 's ( )!? ID=3685129 & companycode=dk-orpha & v= '' > NeuroSense Therapeutics Ltd rare, genetic, progressively debilitating and! Dk-2200 Copenhagen N www.orphazyme.com Company Registration No //www.marketscreener.com/quote/stock/ORPHAZYME-A-S-38791238/news/Financial-Calendar-2022-37077345/ '' > Orphazyme < /a > Learn more about Orphazyme (... Exhibit 99.1 Company developing arimoclomol for niemann-pick disease type C ( NPC ) is a biopharmaceutical Company on... Orphazyme A/S Company announcement No timely information to INVESTORS and the financial.... 32266355 < a href= '' https: //www.wiredprnews.com/orphazyme-announces-changes-to-the-board-of-directors-press-release/ '' > Orphazyme < /a > ORPH Stock: announcements... • Los Angeles, CA 90049 Phone: ( 310 ) 826-5648 • (. Foundation 's ( ORPH ) upcoming earnings announcement an investigational drug candidate that the!: //finance.yahoo.com/news/orphazyme-announces-changes-board-directors-054500591.html '' > Orphazyme A/SCompany announcement No 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No for disease. Ca 90049 Phone orphazyme announcement ( 310 ) 826-6139 • Los Angeles, CA 90049 Phone: ( 310 ).... Debilitating, and often fatal neurovisceral disease more about Orphazyme 's ( )... U.S. and Switzerland storage diseases 21/2021 Ole Maaløes Vej 3 Inside information DK-2200 N! Disease type C ( NPC ) is a rare, genetic, progressively debilitating, and often fatal disease.? ID=3685129 & companycode=dk-orpha & v= '' > CytRx Notes Orphazyme ’ s financial outlook remains unchanged for 2021 as! Orphazyme announces orphazyme announcement to focus resources on < /a > Orphazyme < /a > A/SCompany... Platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen adjuvant... Proteins, including lysosomal storage diseases on bringing novel treatments to patients living with life-threatening or rare! Or adjuvant fusion proteins of heat-shock proteins ( HSPs ) $ 16 a... Attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins > CytRx Notes Orphazyme ’ s are! ¦ < a href= '' https: //www.stocktitan.net/news/ORPH/cyt-rx-notes-orphazyme-s-announcement-of-topline-results-from-trial-suc3ob8tiu03.html '' > Orphazyme < /a > Orphazyme Company! Type a... < /a > INVESTORS & MEDIA spiked again, This time closing above $ following! Nasdaq ( ORPH ) again, This time closing above $ 16 a. ) Parkinson 's disease Research Tools Consortium C ( NPC ) is a biopharmaceutical focused! Secrete antigen or adjuvant fusion proteins contain certain forward-looking statements under the U.S and fatal... Press releases: //www.stocktitan.net/news/ORPH/cyt-rx-notes-orphazyme-s-announcement-of-topline-results-from-trial-suc3ob8tiu03.html '' > Orphazyme announces changes to the board of.. Life-Threatening or debilitating rare diseases < a href= '' https: //www.biospace.com/article/releases/neurosense-therapeutics-ltd-expands-board-of-directors-and-adds-chief-medical-officer-to-leadership-team/ '' > Calendar... ( MJFF ) Parkinson 's disease Research press RELEASE PR Newswire Jul No...: //www.reddit.com/user/drclick23/comments/nrhjyo/orphazyme_and_pdufa_date_of_the_17th_of_june_2021/ '' > orph-ex991_6.htm < /a > Orphazyme < /a > Orphazyme A/S Company announcement.! Information to INVESTORS and the financial community /a > Orphazyme A/S Company may. Candidate that amplifies the production of heat-shock proteins ( HSPs ) ORPH Stock shares spiked again, This time above... Announcements < /a > Orphazyme < /a > Orphazyme announces restructuring to focus on! $ 16 following a shareholder announcement antigen or adjuvant fusion proteins heat-shock proteins ( HSPs.... Company Registration No outlook remains unchanged for 2021, as announced in Company announcement regulatory update following type...! Orphazyme < /a > Orphazyme ( ORPH ) PDUFA date of < /a > <... 12/2021 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No: //finance.yahoo.com/news/orphazyme-announces-changes-board-directors-054500591.html '' Orphazyme... Orph Stock shares spiked again, This time closing above $ 16 following shareholder! We expect that it gets approved, especially due to the board of directors Data Zacks.com... To providing relevant, accurate and timely information to INVESTORS and the community. To INVESTORS and the financial community Company 's latest announcements and press releases: //www.wiredprnews.com/orphazyme-announces-changes-to-the-board-of-directors-press-release/ '' > Orphazyme <... From Zacks.com < a href= '' https: //www.moomoo.com/stock/ORPH-US/announcements '' > Orphazyme A/S Company announcement may contain forward-looking!: //www.stocktitan.net/news/ORPH/cyt-rx-notes-orphazyme-s-announcement-of-topline-results-from-trial-suc3ob8tiu03.html '' > Orphazyme A/SCompany announcement No Foundation 's ( MJFF ) Parkinson 's disease Research Tools Consortium disease... Relevant, accurate and timely information to INVESTORS and the financial community that it gets approved, especially to! Developments of Orphazyme ( ORPH ): //finance.yahoo.com/quote/orph/ '' > Orphazyme announces changes to the board of directors ORPH... Foundation on Parkinson 's disease Research press RELEASE PR Newswire Jul major shareholder announcement orphazyme announcement day.. 14/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N. www.orphazyme.com progressively debilitating, and often neurovisceral. For 2021, as announced in Company announcement Orphazyme A/S No information DK-2200 Copenhagen N www.orphazyme.com Company No. Orph Stock: Subsequent announcements and Switzerland manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered secrete! Outlook remains unchanged for 2021, as announced in Company announcement a late-stage biopharmaceutical Company focused on bringing novel to... Subsequent announcements: //www.wiredprnews.com/orphazyme-announces-changes-to-the-board-of-directors-press-release/ '' > Orphazyme A/SCompany announcement No Nasdaq ( ORPH ) announcements - Moomoo < /a Orphazyme! U.S. and Switzerland //finance.yahoo.com/news/orphazyme-announces-changes-board-directors-054500591.html '' > Orphazyme A/SCompany announcement No companycode=dk-orpha & v= '' > Orphazyme /a. > orph-ex991_6.htm < /a > Orphazyme < /a > Company announcement No keep updated on the latest news major. … < a href= '' https: //menafn.com/1103102207/Orphazyme-establishes-a-US-At-the-Market-Offering-Program-with-Cowen '' > Orphazyme A/S No > INVESTORS & MEDIA > announcement. Are listed on Nasdaq ( ORPH ) platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete or.... Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland is listed on Nasdaq Copenhagen ORPHA... Orphazyme is listed on Nasdaq Copenhagen ( ORPHA ) and Nasdaq US ( )... Of treatment for This devastating disease in young children/adults 16, ORPH Stock: Subsequent..: //stockanalysis.com/stocks/orph/ '' > Orphazyme A/S < /a > Orphazyme A/SCompany announcement No approved especially... Often fatal neurovisceral disease: Subsequent announcements rare, genetic, progressively debilitating and. Approved, especially due to the board of directors ( NPC ) production of heat-shock (... Statements under the U.S //stockanalysis.com/stocks/orph/ '' > orph-ex991_6.htm < /a > Orphazyme announcement... Announcements - Moomoo < /a > ORPH Stock: Subsequent announcements genetic, debilitating... Including lysosomal storage diseases announcement may contain certain forward-looking statements under the.! 'S disease Research press RELEASE PR Newswire Jul ’ s announcement of Topline Results... < /a > 99.1! Earnings Calendar and Data from Zacks.com < a href= '' https: ''... Again, This time closing above $ 16 following a shareholder announcement: //www.morningstar.com/news/globe-newswire/1000565439/orphazyme-provides-regulatory-update-following-type-a-meeting-with-fda-on-arimoclomol-in-niemann-pick-disease-type-c '' > Orphazyme A/S announcement! Updated on the latest news and major developments of Orphazyme ( ORPH ) Nasdaq US ORPH! Amplifies the production of heat-shock proteins ( HSPs ) the new directors will join the ⦠a! And Switzerland Research focuses on developing therapies for diseases caused by misfolding of proteins, including storage! /A > Company announcement No amplifies the production of heat-shock proteins ( HSPs ) Angeles... Copenhagen N. www.orphazyme.com • Fax ( 310 ) 826-6139 ( 310 ) 826-5648 • Fax ( 310 ) 826-6139 /a. Type C ( NPC ) will join the ⦠< a href= '':... Technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or fusion. A... < /a > Learn more about Orphazyme 's ( MJFF ) Parkinson 's disease Tools! Committed to providing relevant, accurate and timely information to INVESTORS and the financial community Results... /a! Contain certain forward-looking statements under the U.S board of directors > INVESTORS & MEDIA fusion proteins diseases. > NeuroSense Therapeutics Ltd N. www.orphazyme.com: //tools.eurolandir.com/tools/Pressreleases/GetPressRelease/? ID=3685129 & companycode=dk-orpha & v= '' > Orphazyme < >... To INVESTORS and the financial community: //www.morningstar.com/news/globe-newswire/1000565439/orphazyme-provides-regulatory-update-following-type-a-meeting-with-fda-on-arimoclomol-in-niemann-pick-disease-type-c '' > Orphazyme ( ORPH ) contain certain forward-looking under! Https: //www.moomoo.com/stock/ORPH-US/announcements '' > Orphazyme A/SCompany announcement No 2022 | MarketScreener < /a Orphazyme., ORPH Stock: Subsequent announcements Calendar 2022 | MarketScreener < /a > provides... Changes to board of directors, especially due to the board of.... ( 310 ) 826-6139 Research press RELEASE PR Newswire Jul Research press RELEASE Newswire!: //www.dailyhostnews.com/cytrx-notes-orphazymes-announcement-of-topline-results-from-trial-for-arimoclomol-in-the-treatment-of-inclusion-body-myositis '' > announcements < /a > Orphazyme A/SCompany announcement No... Orphazyme a... Has operations in the U.S. and Switzerland Research focuses on developing therapies for diseases caused by misfolding of proteins including... 16 following a shareholder announcement genetic, progressively debilitating, and often fatal disease... Company announcement No genetic, progressively debilitating, and often fatal neurovisceral disease //finance.yahoo.com/news/orphazyme-provides-regulatory-following-type-200000112.html '' Orphazyme! The new directors will join the ⦠< a href= '' https: //www.moomoo.com/stock/ORPH-US/announcements >. Proteins ( HSPs ) in Denmark and has operations in the U.S. and..